Anika Therapeutics, Inc.
ANIK
$15.05
$0.020.13%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 151.80M | 118.30M | 121.01M | 123.39M | 120.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 151.80M | 118.30M | 121.01M | 123.39M | 120.79M |
| Cost of Revenue | 80.16M | 58.62M | 37.08M | 37.85M | 37.51M |
| Gross Profit | 71.64M | 59.68M | 83.93M | 85.54M | 83.28M |
| SG&A Expenses | 76.77M | 49.86M | 55.57M | 59.46M | 59.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 186.25M | 127.94M | 112.66M | 118.84M | 119.20M |
| Operating Income | -34.45M | -9.64M | 8.35M | 4.55M | 1.59M |
| Income Before Tax | -31.29M | -6.05M | 14.53M | 10.70M | 3.16M |
| Income Tax Expenses | 5.72M | 12.25M | 9.48M | 8.30M | 6.60M |
| Earnings from Continuing Operations | -37.01 | -18.29 | 5.05 | 2.40 | -3.44 |
| Earnings from Discontinued Operations | -19.38M | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.39M | -97.52M | -74.18M | -76.83M | -82.67M |
| EBIT | -34.45M | -9.64M | 8.35M | 4.55M | 1.59M |
| EBITDA | -25.95M | 239.00K | 19.58M | 17.28M | 15.81M |
| EPS Basic | -3.84 | -6.64 | -5.06 | -5.24 | -5.64 |
| Normalized Basic EPS | -1.36 | -0.31 | 0.46 | 0.30 | 0.17 |
| EPS Diluted | -3.85 | -6.65 | -5.07 | -5.25 | -5.65 |
| Normalized Diluted EPS | -1.36 | -0.31 | 0.46 | 0.30 | 0.17 |
| Average Basic Shares Outstanding | 58.88M | 58.96M | 58.83M | 58.68M | 58.63M |
| Average Diluted Shares Outstanding | 58.93M | 58.96M | 58.83M | 58.68M | 58.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
